Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.174.62 ]

🍽️ imiquimod,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Local Skin Reactions: Common side effects of imiquimod include redness, swelling, itching, burning, and flaking at the application site. These reactions are usually mild to moderate and often resolve with continued use.
  2. Pain or Discomfort: Some individuals may experience pain or discomfort at the site of application, particularly during the initial stages of treatment.
  3. Skin Erosion or Ulceration: Rarely, imiquimod may cause severe skin reactions such as erosion, ulceration, or blistering at the application site.
  4. Flu-Like Symptoms: Systemic side effects such as fever, fatigue, headache, and muscle aches may occur, especially with higher doses or prolonged use.
  5. Localized Pigment Changes: Imiquimod may cause changes in skin pigmentation, including hypopigmentation (lightening of the skin) or hyperpigmentation (darkening of the skin) at the treatment site.
  6. Allergic Reactions: Rarely, individuals may experience allergic reactions to imiquimod, characterized by rash, itching, swelling, or difficulty breathing. Immediate medical attention is necessary if allergic symptoms occur.
  7. Eye Irritation: Imiquimod cream should not come into contact with the eyes, as it may cause irritation. If accidental eye exposure occurs, it should be flushed with water immediately, and medical advice sought if irritation persists.
  8. Increased Photosensitivity: Imiquimod may increase the skin's sensitivity to sunlight, leading to sunburn or worsening of existing skin conditions. Patients should be advised to use sunscreen and protective clothing while undergoing treatment.
;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of imiquimod,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by imiquimod,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Phocaeicola genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Clostridium genus Decreases 👪 Source Study Pathogen
Coprococcus genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Parabacteroides distasonis species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Coprococcus comes species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Streptococcus parasanguinis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of imiquimod,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 1 0.3 2.33
Age-Related Macular Degeneration and Glaucoma 0.1 0.4 -3
Allergic Rhinitis (Hay Fever) 1 1
Allergies 0.4 0.4 0
Allergy to milk products 0.6 0.4 0.5
Alopecia (Hair Loss) 0.8 0.8
Alzheimer's disease 0.6 1.4 -1.33
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.7 0.7
Ankylosing spondylitis 0.9 0.2 3.5
Anorexia Nervosa 0.4 0.7 -0.75
Antiphospholipid syndrome (APS) 0.3 0.3
Asthma 0.4 0.3 0.33
Atherosclerosis 0.6 -0.6
Atrial fibrillation 1 0.6 0.67
Autism 3.2 2.9 0.1
Barrett esophagus cancer 0.1 -0.1
Bipolar Disorder 0.6 0.4 0.5
Brain Trauma 0.3 -0.3
Carcinoma 0.8 0.6 0.33
Celiac Disease 1.3 0.6 1.17
Cerebral Palsy 0.5 0.3 0.67
Chronic Fatigue Syndrome 1.6 3.9 -1.44
Chronic Kidney Disease 0.6 0.4 0.5
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 0.3 0.4 -0.33
Chronic Urticaria (Hives) 0.5 0.4 0.25
Coagulation / Micro clot triggering bacteria 0.5 0.2 1.5
Colorectal Cancer 1.1 1.1
Constipation 1.2 0.1 11
Coronary artery disease 0.3 -0.3
COVID-19 2.5 2.3 0.09
Crohn's Disease 2.3 1.4 0.64
cystic fibrosis 0.3 -0.3
deep vein thrombosis 0.2 -0.2
Depression 4 3.5 0.14
Dermatomyositis 0.1 0.1
Eczema 0.9 -0.9
Endometriosis 1 1
Epilepsy 0.7 1.5 -1.14
Fibromyalgia 1.7 1.7 0
Functional constipation / chronic idiopathic constipation 2.6 1.4 0.86
gallstone disease (gsd) 0.8 0.1 7
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.4 0.1 13
Generalized anxiety disorder 0.9 -0.9
giant cell arteritis 0.4 -0.4
Glioblastoma 0.1 -0.1
Gout 0.3 -0.3
Graves' disease 0.6 0.1 5
Halitosis 0.2 0.1 1
Hashimoto's thyroiditis 0.3 0.2 0.5
Hidradenitis Suppurativa 0.1 0.1
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.8 0.8
hypercholesterolemia (High Cholesterol) 0.4 0.4
hyperglycemia 0.6 -0.6
hypertension (High Blood Pressure 0.8 1.1 -0.38
Hypothyroidism 0.3 -0.3
Hypoxia 0.6 0.6
IgA nephropathy (IgAN) 0.9 -0.9
Inflammatory Bowel Disease 0.7 2.3 -2.29
Insomnia 0.3 0.3 0
Intelligence 1.2 1.2
Intracranial aneurysms 0.6 0.6
Irritable Bowel Syndrome 0.7 2.2 -2.14
Liver Cirrhosis 1.5 1.1 0.36
Long COVID 2.3 1 1.3
Low bone mineral density 0.4 -0.4
ME/CFS with IBS 0.5 0.8 -0.6
ME/CFS without IBS 0.6 1.1 -0.83
Metabolic Syndrome 1.9 3.4 -0.79
Mood Disorders 5.1 3.5 0.46
multiple chemical sensitivity [MCS] 0.1 0.1
Multiple Sclerosis 0.7 3.2 -3.57
Multiple system atrophy (MSA) 0.2 0.2
Neuropathy (all types) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.5 0.5 0
Obesity 1.5 1.5 0
obsessive-compulsive disorder 2.6 0.5 4.2
Osteoarthritis 0.7 0.7
Osteoporosis 0.6 0.2 2
pancreatic cancer 0.1 0.1
Parkinson's Disease 0.8 1 -0.25
Polycystic ovary syndrome 2 0.5 3
Postural orthostatic tachycardia syndrome 0.4 0.3 0.33
Premenstrual dysphoric disorder 0.4 -0.4
primary biliary cholangitis 0.5 -0.5
Psoriasis 0.9 1.8 -1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.1 1.4 -0.27
Rosacea 0.5 -0.5
Schizophrenia 2.6 0.7 2.71
scoliosis 0.3 0.3
Sjögren syndrome 0.5 1.1 -1.2
Sleep Apnea 0.3 0.6 -1
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.1
Stress / posttraumatic stress disorder 1.1 0.6 0.83
Systemic Lupus Erythematosus 1.4 0.1 13
Tic Disorder 1 1
Tourette syndrome 0.2 -0.2
Type 1 Diabetes 1.9 1.6 0.19
Type 2 Diabetes 2.5 3.4 -0.36
Ulcerative colitis 1 2.9 -1.9
Unhealthy Ageing 2 0.4 4

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. [35.174.62 ]